Moxifloxacin in the treatment of hospitalised community acquired pneumonia in HIV-infected subjects.

摘要

Community-acquired pneumonia (CAP) remains a common and serious illness, in spite of the availability of potent new antimicrobials and effective vaccines Immunocompromised patients, especially those with human immunodeficiency virus (HIV) infection, have become recognized as a uniquely important population because of their increased risk for CAP and expanded spectrum of potential causes . Newer fluoroquinolones, such as moxifloxacin (MXP), have been designed to improve on the shortcomings of their predecessors, particularly in terms of efficacy and spectrum of activity against target pathogens associated with lower respiratory tract infections. In this study we evaluate the safety and efficacy of MXP administered at 400 mg orally once daily in the treatment of a cohort of HIV-infected patients with hospitalized CAP.